Jeffrey Lee, MD
Geriatric Medicine · Houston, TXNPI 1336125087
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 79.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $398 and has fallen 79.5% since, to $82 in 2025.
Across 48 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$889
- Medtronic$128
- SPR Therapeutics, Inc$33
- Novo Nordisk$18
- Abbott$18
- Collegium Pharmaceutical, Inc.$16
- plus $13 from 1 others
What the payments were for
- Food & beverage$1,115100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 38 | $889 |
| Medtronic | 5 | $128 |
| SPR Therapeutics, Inc | 1 | $33 |
| Novo Nordisk | 1 | $18 |
| Abbott | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,115 in reported general payments places this provider in the 75th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $31,989 |
| MyrbetriqMirabegron | 32 | $8,493 |
| RytaryCarbidopa/Levodopa | 14 | $3,401 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,452 |
| Gabapentin | 74 | $1,172 |
| Levothyroxine Sodium | 158 | $1,123 |
| Irbesartan | 22 | $753 |
| Potassium Chloride | 64 | $719 |
| Quetiapine Fumarate | 46 | $708 |
| Tamsulosin Hcl | 72 | $667 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $626 |
| Trazodone Hcl | 96 | $583 |
| Memantine Hcl ErMemantine Hcl | 27 | $571 |
| Bisoprolol Fumarate | 35 | $557 |
| Amlodipine Besylate | 99 | $503 |
Paid to pharmacies, not to this prescriber.
Other geriatric medicine in Houston
- George TaffetHouston$9K
- Adeeba AkhtarHouston$6K
- Anil ThakerHouston$4K
- Kathryn AgarwalHouston$4K
- Aimee GarciaHouston$3K
- Radhika HariharanHouston$3K
- Jerome WassersteinHouston$3K
- Sistla KrishnaHouston$2K
- Teresa AlbrightHouston$2K
- Rechelle AsirotHouston$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.